Vaccines

Journal Browser

► Journal Browser

Special Issue Information

Dear Colleagues,

The SARS-CoV-2 Pandemic has severely impacted the daily practice of medical professionals all around the world, as a large share of Healthcare Workers has seen their daily activities either disrupted or shifted on settings directly related in the global efforts to contain the effect of the pandemic. Vaccination services have been severely impacted, not only during the early stages of the pandemic, but also in its aftermath, as the global campaign for the delivery of SARS-CoV-2 vaccines has drained human and material resources from more “conventional” vaccine interventions. In the meantime, global attitudes towards vaccines and immunizations have been impacted by an unprecedented infodemic on infectious diseases and public health interventions. In such a setting, this Special Issue will provide an up-to-date appraisal of vaccination rates, vaccination acceptance (specifically focusing on positive and negative effectors), and innovative immunization strategies (including the introduction of monoclonal antibodies in the prevention of infectious diseases likewise RSV). Our aim is to share a broader point of view, specifically including all the professionals (e.g., Gynecologist and Obstetrics, Occupational Physicians, etc.) who are actively involved in vaccination campaigns in specific population groups.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: epidemiological studies, cross-sectional studies on drivers and barriers, ecological studies, prospective studies.

We look forward to receiving your contributions.

Dr. Federico Marchesi
Dr. Matteo Riccò
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

attitudes
healthcare workers
immunizations
knowledge
practices
vaccines
drivers
barriers

Published Papers (2 papers)

Download All Papers

Research

Jump to: Other

13 pages, 409 KiB

Open AccessArticle

Recovery of Routine Immunisation: Mapping External Financing Opportunities for Reaching Zero-Dose Children

by Sarah Tougher, Nikhil Mandalia and Ulla Kou Griffiths

Vaccines 2023, 11(7), 1159; https://doi.org/10.3390/vaccines11071159 - 26 Jun 2023

Viewed by 1186

Abstract

The COVID-19 pandemic has precipitated large declines in childhood vaccination coverage and, consequently, substantial increases in the number of zero-dose children. To effectively respond to these declines, it is necessary to direct resources for recovery. We mapped active external financing for immunisation and primary healthcare in 20 countries with the highest numbers of zero-dose children to promote transparency and donor coordination. We found that countries have disparate access to external financing, with the two upper-middle-income countries (Brazil and Mexico) only having access to loans from the International Bank for Reconstruction and Development. Domestic resource mobilization is, therefore, key in these two countries, although fiscal space is likely constrained. Four additional countries (Angola, Indonesia, Philippines, and Vietnam) do not have allocations from Gavi, the Vaccine Alliance for Health Systems Strengthening, or Equity Accelerator Funding, but are eligible for support under Gavi’s Middle-Income Countries Approach. Our methods, which focus on current donor financing, are novel and reveal substantial variations in access to external financing to support immunisation in high-burden countries. The available data differ considerably across financing mechanisms, making it difficult to synthesise the results across funding sources. Full article

(This article belongs to the Special Issue Immunization Strategies and Vaccine Uptake after the SARS-CoV-2 Pandemic)

Other

Jump to: Research

9 pages, 1221 KiB

Open AccessPerspective

A Practical Guide to Full Value of Vaccine Assessments

by Caroline Trotter, Birgitte Giersing, Ann Lindstrand, Naor Bar-Zeev, Tania Cernuschi, Lauren Franzel-Sassanpour, Martin Friede, Joachim Hombach, Maarten Jansen, Mateusz Hasso-Agopsowicz, Mitsuki Koh, So Yoon Sim, Dijana Spasenoska, Karene Hoi Ting Yeung and Philipp Lambach

Vaccines 2024, 12(2), 201; https://doi.org/10.3390/vaccines12020201 - 16 Feb 2024

Cited by 1 | Viewed by 1587

Abstract

Articulating the wide range of health, social and economic benefits that vaccines offer may help to overcome obstacles in the vaccine development pipeline. A framework to guide the assessment and communication of the value of a vaccine—the Full Value of Vaccine Assessment (FVVA)—has been developed by the WHO. The FVVA framework offers a holistic assessment of the value of vaccines, providing a synthesis of evidence to inform the public health need of a vaccine, describing the supply and demand aspects, its market and its impact from a health, financial and economic perspective. This paper provides a practical guide to how FVVAs are developed and used to support investment in vaccines, ultimately leading to sustained implementation in countries. The FVVA includes a range of elements that can be broadly categorised as synthesis, vaccine development narrative and defining vaccine impact and value. Depending on the features of the disease/vaccine in question, different elements may be emphasised; however, a standardised set of elements is recommended for each FVVA. The FVVA should be developed by an expert group who represent a range of stakeholders, perspectives and geographies and ensure a fair, coherent and evidence-based assessment of vaccine value. Full article

(This article belongs to the Special Issue Immunization Strategies and Vaccine Uptake after the SARS-CoV-2 Pandemic)

► Show Figures